Net Loss per Common Share

6 Months Ended

Sep. 30, 2026

Basic net loss per common share is computed by dividing net loss attributable to Roivant Sciences Ltd. by the weighted-average number of common shares outstanding during the period. Diluted net loss per common share is computed by dividing the net loss attributable to Roivant Sciences Ltd. by the diluted weighted-average number of common shares outstanding during the period.

For periods of net loss, diluted loss per share is calculated similar to basic loss per share as the effect of including all potentially dilutive common stock equivalents is anti-dilutive. For the three and six months ended September 30, 2026 and 2025, all outstanding common stock equivalents have been excluded from the computation of diluted loss per share because their effect was anti-dilutive due to the net loss.

As of September 30, 2026 and 2025, the following potentially dilutive common stock equivalents were excluded from the computation of diluted net loss per common share:


	September 30, 2026	September 30, 2025
Stock options and performance stock options	68,089,460	128,581,431
Restricted stock units and performance restricted stock units (non-vested)	59,812,191	65,651,310
March 2020 CVARs	—	17,548,368
Earn-Out Shares (non-vested)	—	3,080,387
Other stock based awards and instruments issued	388,793	4,056,994

During the three months ended September 30, 2026, Genevant’s parent, GSL, declared a dividend funded by the Fixed Payment received from Moderna. The related settlement gain was recognized during the year ended March 31, 2026 (see Note 5).

GSL’s outstanding restricted stock units and options participated in the distribution through dividend-equivalent rights. The distribution to these equity awards increased net loss attributable to Roivant Sciences Ltd. by $95.9 million for each of the three and six months ended September 30, 2026, increasing basic and diluted net loss per common share by $0.13 for each period.